Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

NeuPath Health Inc V.NPTH

NeuPath Health Inc. provides chronic pain management services in Canada. It operates a network of medical clinics in Ontario and Alberta that offer assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports-related injuries, and concussions. The company also provides workplace health services and independent medical assessments to employers and disability insurers, as well as legal practices through a network of health care providers comprising cardiologists, dentists, dermatologists, psychiatrists, endocrinologists, gastroenterologists, general practitioners, internal medicine specialists, neurologists, neuropsychiatrists, neuropsychologists, occupational therapists, ophthalmologists, orthopedic surgeons, physiatrists, physiotherapists, psychologists, respirologists, and rheumatologists. In addition, it operates a network of healthcare clinics and related businesses. The company is headquartered in Mississauga, Canada.


TSXV:NPTH - Post by User

User Avatar Image
(431)
•••
  • prophetoffactzX
Comment by prophetoffactzon Apr 15, 2026 10:10pm
26 Views
Post# 36968583

RE:cantechletter.com

RE:cantechletter.comAcumen Capital analyst Nick Corcoran has initiated coverage of NeuPath Health (NeuPath Health Stock Quote, Chart, News, Analysts, Financials TSXV:NPTH) with a “Buy” rating and a $0.95 target, saying the company is well positioned in a recession-resistant healthcare segment supported by rising demand for chronic pain treatment and an aging population.
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities